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of neointimal hyperplasia with varying degrees of suc-
cess.2 No one agent, however, has proved to be suffi-
ciently effective at preventing the neointimal response
in human trials,3 possibly because of the multiple path-
ways involved in this complex response.
Consequently, a significant research focus has
been to discover new agents that can provide insight
into this problem.
Uteroglobin is a steroid-inducible, 15.8-kD
secreted protein first isolated from the uterus of
pregnant rabbits more than 30 years ago.4,5 It has
been known by various names, usually related to the
tissue from which it was isolated or to physical prop-
erties it possesses: Clara cell 10-kD protein, blas-
tokinin, retinol-binding protein, and polychlorinated
biphenyl–binding protein.4,6-8 Since it was first iso-
lated, uteroglobin has been found in nearly all verte-
brates. In fact, the complementary DNA (cDNA)
Vascular smooth muscle cell (SMC) activation is a
key ingredient in the development of neointimal
hyperplasia and subsequent restenosis after angioplasty
and arterial surgery.1 Numerous agents have been
investigated in an attempt to prevent the development
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Adenoviral-mediated uteroglobin gene
transfer inhibits neointimal hyperplasia after
balloon injury in the rat carotid artery
Robert A. Larson, MD, Mina Naji, MS, Joseph V. Lombardi, MD, Ali Naji,
MD, PhD, Brigitte Koeberlein, AS, and Michael A. Golden, MD, Philadelphia, Pa
Objective: Uteroglobin is a protein with potent anti-inflammatory and immunomodula-
tory effects. We hypothesize that induction of uteroglobin expression in the artery wall
by local adenoviral gene transfer will decrease neointimal hyperplasia in the rat carotid
artery after balloon injury.
Methods: Seven male Sprague-Dawley rats underwent balloon injury of the common carotid
artery. After the injury, with flow occluded, the artery was instilled with 50 µL of the ade-
noviral vector encoding uteroglobin gene (Ad.UG) at a concentration of 1.35 × 1011
pfu/mL (n = 7) or 0.68 × 1011 pfu/mL (n = 7) (n = 7). Control animals were similarly
treated: either an adenovirus encoding for β-galactosidase gene (Ad.LacZ) at 1 × 1011
pfu/mL (n = 7) or the phosphate-buffered saline (PBS) vehicle (n = 6) was used. The solu-
tion was allowed to dwell for 20 minutes. The rats were humanely killed after 14 days by
perfusion fixation, and the carotid arteries were sectioned for analysis with computerized
planimetry. The intima-media area ratios were calculated for each artery and compared
with analysis of variance with Bonferroni/Dunn post hoc testing. One additional rat from
the PBS, Ad.LacZ, and Ad.UG (1.35 × 1011 pfu/mL) groups was humanely killed 4 days
after treatment for carotid artery protein extraction and Western blotting.
Results: Uteroglobin protein production was confirmed in the Ad.UG-treated arteries with
Western blotting. Morphometric analysis showed that the Ad.UG group at 1.35 × 1011
pfu/mL had a significantly lower intima-media area ratio than both the Ad.LacZ (P = .002)
and PBS (P = .004) controls. The Ad.UG group at 0.68 × 1011 pfu/mL was also signifi-
cantly different from the Ad.LacZ (P = .003) and PBS (P = .006) controls. There was no
statistical difference between the two control groups or between the two Ad.UG groups.
Conclusion: Adenoviral gene transfer of uteroglobin, delivered intraluminally after arte-
rial injury causes the production of uteroglobin protein and has an inhibitory effect on
neointimal accumulation in the rat model. (J Vasc Surg 2000;32:1111-7.)
and the gene for mouse,9 rat,10 rabbit,11 hamster,12
monkey,13 and human14,15 uteroglobin have been
cloned and characterized, revealing a high degree of
homology among species. Uteroglobin is found in
several organs,16 including the uterus, thymus, pitu-
itary gland, respiratory tract, mammary gland,
prostate gland, and blood; it is primarily produced by
the secretory epithelia of organs that communicate
with the external environment. However, uteroglo-
bin has not been detected in the arterial wall.
Additionally, two putative receptors (uteroglobin-
binding proteins) have been isolated from several
organs that express uteroglobin.17 These binding
proteins are not found in the aorta. In light of the tis-
sue distribution of uteroglobin and its binding pro-
tein, it is likely that uteroglobin has a minimal
physiologic role, if any, in the biology of the arterial
wall and the arterial response to injury.
The function of uteroglobin is not fully under-
stood, but it is known to be one of the most potent
anti-inflammatory and immunomodulatory pro-
teins.18,19 It is thought to play an important role in
maternal tolerance for the implanting embryo18,20
and to modulate the immune response of secretory
epithelia exposed to the foreign antigens.19
Several of the known functions of uteroglobin
could have an impact on the activation of vascular
SMCs and the development of neointimal hyperpla-
sia. The anti-inflammatory properties of uteroglobin
have been well documented, and uteroglobin is a
potent inhibitor of monocyte and macrophage
chemotaxis.21 Inflammation has been shown to play
a role in several models of restenosis and neointimal
hyperplasia, especially in large animals. Uteroglobin
is also a potent inhibitor of serum phospholipase
A222,23 and has been shown to inhibit platelet aggre-
gation.24 Platelets have been shown to play an
important role in the arterial response to injury, and
inhibition of platelet activation can reduce neointi-
mal thickening in animal models.25 Uteroglobin has
also been found to inhibit the ability of several cell
lines to invade the extracellular matrix in vitro.17
The migration of SMCs from the media to the
intima is a critical step in the development of the
neointima after arterial injury.26
With the potential for uteroglobin to affect several
aspects of the arterial response to injury, we hypothe-
sized that the induction of uteroglobin protein pro-
duction within the arterial wall after injury would
reduce the neointimal response. To test this hypothe-
sis, we used the well-established model of a balloon
injury in the rat carotid artery and local gene therapy
with an adenovirus encoding the rat uteroglobin gene.
METHODS
Animals
All animal experimentation was approved by the
Institutional Animal Care and Use Committee of
the University of Pennsylvania. Male Sprague-
Dawley rats (300-350 g; Harlan Sprague-Dawley
Inc, Indianapolis, Ind) were housed in the
University’s colony under standard conditions. All
animals were allowed to acclimate for at least 48
hours before experimentation.
Adenoviral vectors
The adenovirus encoding the rat uteroglobin
gene (Ad.UG) was created by subcloning the rat
cDNA (generous gift from Dr Gurmukh Singh,
Pittsburgh VA Medical Center) into the E1, E3
deleted, human adenovirus serotype 5 mutant
dl7001 vector as described elsewhere.27,28 The ade-
novirus encoding the β-galactosidase gene
(Ad.LacZ) was obtained from the Vector Core of
the Institute for Human Gene Therapy of the
University of Pennsylvania, and like the Ad.UG vec-
tor, was constructed with the E1, E3 deleted,
human adenovirus serotype 5 mutant dl7001 vector.
Rat carotid artery injury model
The animals were anesthetized with an intramus-
cular injection of ketamine (50 mg/kg; Phoenix
Pharmaceuticals, St Joseph, Mo), xylazine (5 mg/kg;
Phoenix Pharmaceuticals), and acepromazine (1
mg/kg; Fermenta Animal Health Products, Kansas
City, Mo). A standard balloon carotid artery injury
was performed as described by Clowes et al1 with a
2F Fogarty balloon catheter (Baxter Healthcare,
Irvine, Calif). After the injury, the lumen of the
artery was irrigated with phosphate-buffered saline
(PBS) (Mediatech, Inc, Ormond Beach, Fla) and
then instilled with 50 µL of either an adenoviral vec-
tor or PBS at a pressure of 120 to 150 mm Hg. The
dwell was maintained for 20 minutes, after which the
solution was aspirated and flow was restored to the
common and internal carotid arteries. The proximal
extent of the injury was marked with a silk suture
placed adjacent to the artery. The wound was closed
with absorbable suture and the animal allowed to
recover. Ad libitum food and water access was rein-
stituted 8 hours after the procedure and continued
until the animal was humanely killed.
For morphometric analysis, 27 Sprague-Dawley
rats underwent carotid artery injury and were divided
into four treatment groups, each receiving a different
dwell solution: (1) Ad.UG at 1.35 × 1011 pfu/mL, 
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n = 7; (2) Ad.UG at 0.68 × 1011 pfu/mL, n = 7; (3)
Ad.LacZ at 1.0 × 1011 pfu/mL, n = 7; and (4) PBS
(vehicle), n = 6. Additionally, three rats (one Ad.UG at
1.35 × 1011 pfu/mL, one Ad.LacZ, and one PBS
dwell) were treated with the above protocol and har-
vested at 4 days for Western blotting.
Tissue preparation
Frozen tissue. Tissue obtained for Western analy-
sis was obtained from animals humanely killed 4 days
after injury by means of exsanguination under deep
anesthesia. The common carotid artery was cleanly
dissected from the neck, irrigated with PBS, and snap
frozen in liquid nitrogen for protein extraction.
Perfusion fixation. For morphometric analysis,
the animals were humanely killed by means of per-
fusion fixation 2 weeks after injury. Twenty minutes
before they were killed and under deep anesthesia,
the animals received a 1-mL intravenous injection of
5% Evans blue to allow for identification of the
deendothelialized segment of the carotid artery. A
laparotomy was then performed, and the abdominal
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Fig 1. Uteroglobin protein detection by Western blot. Western blot detection of rat uteroglobin in pro-
tein extracts from arteries treated with (1) Ad.UG (1.35 × 1011 pfu/mL), (2) Ad.LacZ, (3) PBS vehicle,
along with untreated rat aorta (Ao) and rat lung. Equal amounts of protein (8 µg) were loaded onto each
lane. The primary antibody was a rabbit antirat uteroglobin polyclonal. PBS, Phosphate-buffered saline.
Fig 2. Morphometry results. Morphometry data from animals humanely killed 2 weeks after injury, expressed
as I/M area ratio. Group treated with Ad.UG at 1.35 × 1011 pfu/mL had significantly lower I/M ratio than
groups treated with PBS (P = .004) and Ad.LacZ (P = .002). Similarly, Ad.UG group at 0.68 × 1011 pfu/mL
had significantly lower I/M ratio than PBS (P = .006) and Ad.LacZ (P = .003) controls. The two Ad.UG
groups were not statistically different, nor were PBS and Ad.LacZ groups. Results shown as mean ± SEM
and are significant at P < .008. I/M, Intima-media; PBS, phosphate-buffered saline.
aorta was cannulated with a 22-gauge catheter. The
right external jugular vein was opened, and the ani-
mal was perfused with lactated Ringer’s solution at a
pressure of 120 to 150 mm Hg until the effluent ran
clear. The animals were then perfused with 10%
buffered formalin (Fisher Scientific, Pittsburgh, Pa)
at a pressure of 120 to 150 mm Hg for 15 minutes.
The necks were harvested and allowed to fix in 10%
buffered formalin for an additional 24 hours. After
fixation, the carotid arteries were dissected from the
necks and divided at the midpoint of the injury as
indicated by the staining with Evans blue. The Evans
blue staining was uniform among all the animals that
were humanely killed; there were no skip areas
within the injured region macroscopically. The prox-
imal and distal segments were imbedded in paraffin,
sectioned, and stained with hematoxylin and eosin
for morphometric analysis. No arteries were found
to be thrombosed during this study.
Morphometric analysis
Cross-sectional slides of perfusion-fixed carotid
arteries, stained with hematoxylin and eosin, were
used to measure the degree of neointimal thickening.
Two sections near the center of the Evans blue (ie,
injured) region of the artery were measured. A light
microscope fitted with a computer-interfaced image
analyzer (Bioquant System IV, R&M Biometrics Inc,
Nashville, Tenn) was used to measure the intimal and
medial areas at 125× magnification. The intima-
media (I/M) area ratio was calculated for each of the
two sections per artery, the average of which was
used as an index of neointimal hyperplasia.
Western analysis
Harvested tissue was snap frozen in liquid nitro-
gen and suspended in a cell lysis solution containing
1% sodium dodecyl sulfate, 1 µmol/L phenylmethyl-
sulfonyl fluoride, and 10 µg/mL leupeptin for 30
minutes at room temperature. After centrifugation, an
aliquot of the supernatant was used to determine the
protein concentration with BCA assay (Pierce,
Rockford, Ill). The remainder was diluted 2:1 in 3×
sodium dodecyl sulfate sample buffer-containing β-
mercaptoethanol and boiled for 5 minutes. Equal
amounts (8 µg) of total protein were loaded onto a
15% polyacrylamide gel (Biorad, Hercules, Calif),
electrophoresed, and transferred to nitrocellulose.
The blot was blocked overnight at 4°C in 5% solution
of powdered milk in Tris-buffered saline with 0.1%
Tween 20. The blot was then incubated for 1 hour
with a rabbit polyclonal antirat uteroglobin antibody
(generous gift from Dr Gurmukh Singh, Pittsburgh
VA Medical Center) and diluted to 1:1000 in Tris-
buffered saline with 0.1% Tween 20. The secondary
antibody was horseradish peroxidase–linked donkey
antirabbit (Amersham, Piscataway, NJ) at 1:10000
dilution. The blots were developed with ECL plus
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Fig 3. Representative carotid artery histology. Hematoxylin and eosin–stained cross sections of carotid arte-
rial walls harvested 2 weeks after injury and treatment with PBS (A), Ad.LacZ (B), and Ad.UG at 1.35 ×
1011 pfu/mL (C).
chemiluminescent kit (Amersham, Piscataway, NJ)
and exposed to Kodak X-Omat AR film (Eastman
Kodak, Rochester, NY).
Statistical analysis
Results are reported as mean ± SEM. Values
from Ad.UG-treated animals were compared with
Ad.LacZ- and PBS-treated control animals with
analysis of variance with Bonferroni/Dunn post hoc
testing. Differences were considered significant at
the level of P less than .008 (StatView 4.5; SAS, Inc,
Cary, NC).
RESULTS
Ad.UG transgene expression. Animals killed 4
days after injury and treatment were examined for
the presence of uteroglobin protein production in
the carotid artery by means of Western blotting
analysis. As shown in the Western blot (Fig 1), the
artery treated with Ad.UG was shown to produce
the uteroglobin protein, which was seen as a 10-kD
band (although uteroglobin is a 15-kD protein, it
migrates electrophoretically, like a 10-kD protein29).
Samples from the Ad.LacZ and PBS controls, as well
as the aortic sample, did not show uteroglobin pro-
tein. Rat lung, known to contain a rich supply of
uteroglobin in the bronchiolar epithelium, served as
a positive control.
Effect of Ad.UG on the arterial response to
injury. The morphologic effect of treatment of bal-
loon-injured arteries with Ad.UG was studied by
measuring the I/M ratio at 14 days after injury, as
described above. As shown in Fig 2, a significant
reduction in the I/M ratio was observed in the
Ad.UG-treated animals at 1.35 × 1011 pfu/mL
(0.50 ± 0.07) compared with the Ad.LacZ (0.89 ±
0.08, P = .002) and PBS (0.87 ± 0.09, P = .004)
controls. In addition, a significant reduction in the
I/M ratio was also observed in the Ad.UG-treated
animals at 0.68 × 1011 pfu/mL (0.51 ± 0.08) com-
pared with the Ad.LacZ (P = .003) and PBS (P =
.006) controls. The difference between the PBS and
Ad.LacZ controls was not significant. Similarly, the
difference between the two Ad.UG-treated groups
was not significant. Representative photomicro-
graphs of the arterial histology for the PBS,
Ad.LacZ, and Ad.UG groups are shown in Fig 3.
DISCUSSION
Uteroglobin is a multifunctional protein that has
been studied for more than 30 years. Nevertheless,
the full scope of its physiologic significance is still
being uncovered. It is certainly one of the most
potent immunomodulatory agents in vivo, and it is
a potent inhibitor of serum phospholipase A2 and
platelet aggregation. Currently, a great deal of effort
is being directed at the use of recombinant utero-
globin protein30 to study inflammatory and fibrotic
diseases, such as asthma,31,32 sarcoidosis,31 and
neonatal respiratory distress syndrome.33,34 To date,
however, there have been few data on the effects or
functions of uteroglobin on the arterial system or on
vascular SMCs.
We have shown that adenovirally mediated utero-
globin gene transfer can induce the production of
uteroglobin protein in the carotid artery and that this
reduces the degree of neointimal hyperplasia that
occurs after balloon injury. The mechanism for this
effect remains to be determined. Uteroglobin likely
has an inhibitory effect on vascular SMCs, either
directly or through its modulation of local platelet
function or the inflammatory response. Further study
is needed to determine the effect of Ad.UG treat-
ment on SMC migration, proliferation, and apopto-
sis after arterial injury. Alternate strategies would be
to use systemic or local recombinant uteroglobin to
modulate the arterial response to injury. In the native
artery, however, it appears unlikely that uteroglobin
plays an important role in the response to injury; the
lack of uteroglobin and its binding proteins in the
aorta support this assertion. 
The ability to induce the production of a natu-
rally occurring protein that can reduce the degree of
neointimal thickening in vessels is important.
Although uteroglobin has been studied for the past
three decades, this project has used uteroglobin in a
novel fashion, with a beneficial effect on the arterial
wall. The use of a locally delivered adenovirus
encoding uteroglobin may prove to be a valuable
tool in the study of the complex biology of the arte-
rial response to injury. Local induction of uteroglo-
bin expression may also represent a novel local
therapy to prevent restenosis after peripheral and
coronary arterial interventions.
We would like to thank Dr Gurmukh Singh for pro-
viding the rat uteroglobin cDNA and the antirat utero-
globin antibody. We are also indebted to Dr Zandong
Yang for his technical expertise in subcloning the rat
uteroglobin cDNA into the adenoviral vector.
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DISCUSSION
Dr Peter J. Pappas (Newark, NJ). Dr Larson and his col-
leagues at the University of Pennsylvania have investigated
the role of adenoviral gene transfer of uteroglobin, also
known as retinal-bonding protein, in a well-established rat
carotid balloon injury model first described by Dr Clowes.
They measured intima/media area ratios for intimal hyper-
plasia assessment and performed Western blots to prove
active protein production caused by their gene transfection.
The results indicate that uteroglobin gene transfection
inhibits intimal hyperplasia and causes active protein pro-
duction in arteries that don’t normally express uteroglobin. 
I have several questions for the authors. Long-term
expression of genes introduced to arteries with adenoviral
vectors is impeded by the concurrent expression of aden-
oviral proteins that are recognized by the host immune sys-
tem. As a result, most transfected genes are turned off after
3 weeks. So my first question relates to your viral vector.
Does it cause expression of adenoviral proteins at the cell
surface, or is your vector one of the newer generation vec-
tors that have been engineered to delete their detection
proteins? If it’s a standard E1-E3 replication deficient virus,
do you anticipate that you’ll see uteroglobin expression
after 3 weeks? Your current study only looked at 4-day pro-
tein expression and 14-day intimal hyperplasia responses. 
Along the same lines, is long-term uteroglobin protein
expression needed? Your group has previously demon-
strated that adenoviral gene transfection with antisense
oligonucleotides to basic FGF in a rat and rabbit model
almost completely inhibited intimal hyperplasia in the short-
and long-term. The implication of these experiments was
that inhibiting the initial injury was more important than
prolonged continuous expression. Given the fact that utero-
globin appears to diminish intimal hyperplasia and not com-
pletely inhibit it, do you think prolonged expression will
continue to inhibit intimal hyperplasia formation? 
And finally, my third question relates to your model.
Your design was impeccable, and all the appropriate con-
trols were used. However, I can show you a dozen papers
in which investigators have added their genes of interest
and were able to demonstrate intimal hyperplasia inhibi-
tion in this model. As a result, most investigators feel that
the rat carotid injury model is good for investigating
mechanisms but has little correlation to human disease. So
what mechanisms do you propose investigating in the
future, and do you see potential clinical applications for
this technology in the future?
I enjoyed reading this manuscript very much and look
forward to the author’s responses. Thank you.
Dr Robert A. Larson. Thank you, Dr Pappas. In
response to your first question, yes, the virus that we used
was a standard, first-generation adenovirus. We assume
that like all standard, first-generation viruses, viral proteins
are produced.
Indeed, the inflammatory response that adenoviruses
induce, with or without injury, just placing adenovirus in or
on the artery, can be dramatic. One of the things we did
note, however, and this is still a topic that we’re working on,
is that the degree of inflammation that develops in the peri-
adventitial region after treatment with uteroglobin virus is
markedly decreased compared with the degree of inflamma-
tion that occurs after treatment with LacZ virus or with the
other viruses that we’ve used in our lab in the past. We are
assuming at this point that it’s because of the potent anti-
inflammatory activity or function that uteroglobin has.
This actually relates to your second question, too. The
long-term effect is unknown. We have not taken these
experiments out to the traditional 3-month time point,
which is something we are doing. However, if the inflam-
matory response that treatment with the uteroglobin ade-
novirus elicits is significantly decreased, perhaps the
longevity of the uteroglobin protein production is also
increased, and therefore the function could be prolonged.
That is something that we’ll have to determine. 
Even if it isn’t, however, as you had mentioned, the
early effects of arterial injury are extremely important in
the long-term development of neointimal thickening. And
if you’re able to block the effects early on, you can develop
a durable effect. So again, that’s something that we’ll have
to determine and hopefully uteroglobin will be able to
provide such a durable effect. 
In response to your comments about the rat model, I
agree that it is certainly not a good model of human arte-
rial response to injury. However, since this is the first time
that uteroglobin has really been applied in vivo to the arte-
rial system, we wanted to start with a very simple, well-
described, well-understood model, from which we could
derive some mechanistic inferences. 
Our first goal is to determine how the uteroglobin
protein affects smooth muscle cell activation and smooth
muscle cell migration, etc, which are the properties that
have been well defined in this model. So I think from here,
though, we do need to proceed on to different models,
larger animal models, that could more accurately model
the human disease process. I think the final verdict will
really depend on those results as to whether uteroglobin
will be an effective therapy for human disease.
Thank you.
Dr Anton N. Sidawy (Washington, DC). I have a tech-
nical question. We all use this model; however, balloon
injury produces a nonuniform injury of the arterial wall.
How did you choose the location of your sections along
the arterial segment?
Dr Larson. As I mentioned, we injected the animals
with Evans blue prior to sacrifice. This sticks to the colla-
gen of the endothelialized artery. And so, just macroscop-
ically, you can see where the artery was injured. And what
we have seen from prior studies and work we have done
using electron microscopy is that the most uniform area of
injury is actually in the midpoint, in the center of that
endothelialized region. The injury starts off weak and then
becomes its best and then tapers off as you get towards the
other end. So what we tried to do is be uniform in our
application of choosing the midpoint of a deendothelial-
ized region of the artery for all the groups and for all the
rats that we’re studying.
Dr Sidawy. So did you choose one section from each
artery, or multiple sections and then you averaged them? 
Dr Larson. Well, in reality what we did was we took the
artery, divided it at its midpoint, and embedded both ends
down in the paraffin section. So when we took a section, we
automatically got two areas that were very close together,
within a few microns, depending on how big of a slice was
taken. And these two numbers were averaged together,
although the difference between them was negligible.
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